


BREAKTHROUGH SENSORY STIMULATION THERAPY TO TREAT ALZHEIMER'S DISEASE

A unique and totally non-invasive method using sensory stimulation to activate microglia cells to remove beta amyloid plaques, characteristic of the brains of Alzheimer's disease patients



www.cognitotx.com

SALSS CONTACT

Zach Malchano
President

zmalchano@cognitotx.com
Tel +1.617.308.5943

Cognito Therapeutics, Inc.
1218 Massachusetts Ave, Suite 200
Cambridge, MA 02138

SALSS RISING STAR | 2018



COGNITO THERAPEUTICS, INC. | PRIVATE COMPANY

Founded in 2016 and based in Cambridge, Massachusetts, Cognito Therapeutics is a clinical-stage startup developing a non-invasive treatment to restore gamma brain wave function, which plays a role in cognition and neurodegenerative conditions. The company received a Series A financing from Morningside Venture Capital in 2016.

OUR PRODUCTS & SERVICES

Alzheimer's disease (AD) is a progressive neurodegenerative condition that remains one of the most serious and rapidly developing health challenges at an individual, family and societal level. In the US, an estimated 46.8 million patients are living with Alzheimer's.

Cognito's patented technology is based on discoveries at MIT's Dept. of Brain and Cognitive Sciences, which showed that pulsed light stimulation of the brain could activate an immune response by microglia cells to remove beta amyloid plaques, characteristic of the brains of AD patients. Following multiple Phase 1 clinical studies, Cognito is actively enrolling in two Phase 1/2 clinical trials to evaluate the effects of its therapy on patients with MCI and mild- to moderate- AD.

Rather than being exclusively focused on prevention and cure, Cognito aims to pioneer a new model of chronic disease management and care for AD and other neurological conditions with an in-home treatment platform, for use by a patient and their care partners to mitigate symptoms.

WHAT MAKES US UNIQUE

Cognito's unique and totally non-invasive method, based on stimulating neurons with light pulsed in 40Hz range, at the optimal gamma rhythm amplitude has been exclusive licensed from MIT by Cognito Therapeutics on a worldwide basis. Prior to being published (Nature, Dec 2016), Cognito filed 40+ provisional patents to develop a significant IP portfolio to protect this new therapeutic area and additional indications.

Our senior management team has 50+ years in combined experience in the successful development medical devices through regulatory clearance and commercialization.

WHY YOU SHOULD MEET US

Cognito is looking for commercial partners and to raise further financing around clinical development and validation of its approach and devices, and services, which will emphasize the importance of daily quality of life, for both patients and caregivers.

KEY TEAM

Li-Huei Tsai, Ph.D.

- Founder
- Picower Professor of Neuroscience and Director of MIT's Picower Institute of Learning and Memory

Ed Boyden, Ph.D.

- Founder
- Professor of Biological Engineering and Brain and Cognitive Sciences at the MIT Media Lab and MIT McGovern Institute.

Zach Malchano

- President
- 10+ years experience in R&D of innovative medical technologies.

Martin Williams

- VP, BD and Marketing
- 10+ years of experience across medical device development

Fred Tobia

- Vice President, Clinical & Regulatory Affairs, Quality Assurance

*Ref: laccarino, H.F. et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540, 230-235 (2016)

